Through strategic guidance, visionary thinking, and a relentless pursuit of excellence, our senior executives steer SPT Labtech towards achieving its mission of making a real difference to human health through solving advanced laboratory challenges.
Learn more
Board of Directors
Our Board of Directors are committed to driving the long-term success and sustainability of SPT Labtech, providing expert guidance and oversight to execute the company’s ambitious commercial strategy.
Learn more
10
SPT Labtech and 10x Genomics Partner to Automate Single Cell Workflows
Continue reading
SPT Labtech and Agilent Introduce Automated Target Enrichment Protocols for Genomic Workflows
Continue reading
How Novartis Is Shaping the Future of Lab Automation Through Smart Sample Transport
Continue reading
21/06/2016
Most drugs bind to a target’s binding site (orthosteric binding). However, binding to a site distant from the binding site appears to have some very significant advantages over orthosteric binding, one of which is reducing off-target side-effects.
Our latest labCrystal magazine describes an innovative fragment screening strategy to identify potential allosteric drug binding sites of a receptor involved in ion channel diseases, such as Alzheimer’s disease.
Published in PNAS (Spurny, R et al., 2015), this study is part of a collaboration between Dr. Ulens, Associate Professor at Katholieke Universiteit (KU) Leuven, Belgium, and Janssen Pharma, Belgium. It uses X-ray crystallography to screen a recently identified chimera (α7-AChBP) of the native α7 nicotinic acetylcholine receptor and the acetylcholine binding protein. Mutations in these receptors result in a diverse range of inherited neurological disorders and form a drug target for a wide variety of therapeutically used drugs, including smoking cessation aids, anti-emetics, sedative/anxiolytic benzodiazepines, barbiturates, general anesthetics and anthelmintics. The PNAS paper reports on the co-crystallization of 5 allosteric binders that produced reproducible crystals.
“Thanks to the mosquito crystal’s low pipetting volumes, a larger set of conditions could be screened per complex (on average ~1000 conditions) leading to high-throughput identification of crystallization conditions within 1-2 weeks,” commented Dr. Ulens.
X-ray crystallization studies of the allosteric binding complexes were set up using SPT Labtech’s mosquito® crystal automated liquid handler to increase speed, throughput and reproducibility.
Structure determination of the crystals obtained from these screens (Fig 1) resulted in the identification of three allosteric sites of α7-AChBP that were involved in receptor modulation. In combination with electrophysiological recordings on the human α7 nAChR, it was demonstrated that fragment binding at these sites modulated receptor function.

Fig 1. A 200 nanoliter sitting drop pipetted by mosquito crystal, containing two crystals used for actual diffraction data collection.